Finally, integrating STING-activated DCs with combinatorial immunotherapies—such as immune checkpoint inhibitors, oncolytic viruses, or adoptive T cell therapies—could provide a powerful framework for next-generation cancer immunotherapy. This evidence concerns the gene STING1 and cancer.